Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06815497 · ClinicalTrials.gov registry record · Phase 2
Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer
A Phase 2 study of Ovarian Cancer, sponsored by Tyler J Curiel.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
- 2
- Study locations
NCT06815497: Recruiting Phase 2 study of Ovarian Cancer, sponsored by Tyler J Curiel.
NCT06815497 is a Phase 2 study of Ovarian Cancer that is actively recruiting participants, run by Tyler J Curiel. The registered enrollment target is 33 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06815497, a Phase 2 study of Ovarian Cancer, is actively recruiting participants, sponsored by Tyler J Curiel.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
- 2
- Study locations
Study Summary
The primary study objective is to assess progression-free survival in patients with ovarian cancer receiving telmisartan plus selected standard of care chemotherapy regimens versus historical controls.
Primary Outcome
Progression free survival is defined as the time between the initiation of telmisartan to progression, as defined by RECIST criteria, on a computed tomography scan.
Conditions Studied
Interventions
- DRUG Telmisartan
Study Locations (2)
New Hampshire
- Dartmouth Hitchcock - Lebanon
- Dartmouth-Hitchcock Manchester - Manchester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2026-01-21 |
| Est. Completion | 2029-05-14 |
| Phase | Phase 2 |
What NCT06815497 shows while recruiting
NCT06815497 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which Telmisartan is the first listed.
NCT06815497 reports a single indexed study location in New Hampshire.
Frequently Asked Questions
What is clinical trial NCT06815497 about?
NCT06815497 is a clinical study titled "Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer". The primary study objective is to assess progression-free survival in patients with ovarian cancer receiving telmisartan plus selected standard of care chemotherapy regimens versus historical controls.
What is the current status of trial NCT06815497?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2026-01-21. Estimated completion is 2029-05-14.
What conditions does trial NCT06815497 study?
This clinical trial studies the following conditions: Ovarian Cancer.
What interventions are being tested in trial NCT06815497?
The interventions under investigation include: Telmisartan (DRUG).
Who is sponsoring clinical trial NCT06815497?
This trial is sponsored by Tyler J Curiel, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06815497 being conducted?
This trial has 2 study locations across New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06815497's enrollment target sits among peer trials
33 246th of 322 higher than 75 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
RECRUITING · Phase 2
-
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
RECRUITING · Phase 2
-
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
- NCT05225363 · 33 participants · Phase 1
Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI